Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.31 |
| ▸ | TDO2 | P48775 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6119198 | 1.00 | EGFR (0.50) | EGFRPIK3CDPIK3CAFGFR4TDO2 | |
| Phthalazine SCHEMBL8993814 | 0.75 | EGFR (0.83) | EGFRPIK3CDPIK3CATDO2 | |
| SCHEMBL30392621 | 0.73 | EGFR (0.56) | EGFRPIK3CDPIK3CAFGFR4TDO2 | |
| SCHEMBL8874014 | 0.72 | EGFR (0.58) | EGFRPIK3CDPIK3CAFGFR4TDO2 | |
| SCHEMBL137377 | 0.72 | EGFR (0.60) | EGFRPIK3CDPIK3CAFGFR4TDO2 | |
| SCHEMBL29409337 | 0.72 | EGFR (0.60) | EGFRPIK3CDPIK3CAFGFR4TDO2 | |
| Hydrochloric Acid SCHEMBL31066682 | 0.70 | EGFR (0.58) | EGFRPIK3CDPIK3CAFGFR4TDO2 | |
| Hydrochloric Acid SCHEMBL322987 | 0.70 | EGFR (0.58) | EGFRPIK3CDPIK3CAFGFR4TDO2 | |
| SCHEMBL29409356 | 0.70 | EGFR (0.58) | EGFRPIK3CDPIK3CATDO2 | |
| SCHEMBL88606 | 0.70 | EGFR (0.58) | EGFRPIK3CDPIK3CATDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117500803-A | Amino-substituted heterocycles for the treatment of cancers with EGFR mutations | 纽威伦特公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-110740996-B | Covalent small molecule DCN1 inhibitors and methods of treatment using the same | 密执安大学评议会 | 2024-01-09 | — | — | CN | disclosed |
| CN-110603256-B | Pyrimidopyrimidinones useful as WEE-1 kinase inhibitors | 阿尔麦克探索有限公司 | 2022-10-28 | — | — | CN | disclosed |
| US-20220194947-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2022-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220194947-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | WEE1, WEE2, NME1 | EGFR 735/4885PIK3CD 246/4885PIK3CA 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.